View Financial HealthChugai Pharmaceutical 配当と自社株買い配当金 基準チェック /46Chugai Pharmaceutical配当を支払う会社であり、現在の利回りは1.77%で、収益によって十分にカバーされています。主要情報1.8%配当利回り-0.0007%バイバック利回り総株主利回り1.8%将来の配当利回り2.4%配当成長18.4%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向44%最近の配当と自社株買いの更新お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.すべての更新を表示Recent updatesお知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025お知らせ • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024お知らせ • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.お知らせ • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023決済の安定と成長配当データの取得安定した配当: CHGC.Fの配当金支払いは、過去10年間 変動性 が高かった。増加する配当: CHGC.Fの配当金は過去10年間にわたって増加しています。配当利回り対市場Chugai Pharmaceutical 配当利回り対市場CHGC.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CHGC.F)1.8%市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.0%アナリスト予想 (CHGC.F) (最長3年)2.4%注目すべき配当: CHGC.Fの配当金 ( 1.77% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) よりも高くなっています。高配当: CHGC.Fの配当金 ( 1.77% ) はUS市場の配当金支払者の上位 25% ( 4.25% ) と比較すると低いです。株主への利益配当収益カバレッジ: CHGC.Fの 配当性向 ( 44.4% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: CHGC.Fは合理的な 現金配当性向 ( 65.4% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/08 02:38終値2026/06/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chugai Pharmaceutical Co., Ltd. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27 アナリスト機関Atsushi SekiBarclaysMiki SogiBernsteinKoichi MameganoBofA Global Research24 その他のアナリストを表示
お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.
お知らせ • Mar 23Chugai Pharmaceutical Co., Ltd. Announces Discontinuation Of Development Of GYM329 (Emugrobart) In Spinal Muscular Atrophy And Facioscapulohumeral Muscular DystrophyChugai Pharmaceutical Co., Ltd. announced that Roche has decided to discontinue the clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin sweeping antibody, for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). This decision follows a rigorous assessment of data from the Phase II/III MANATEE study (Part 1) in SMA and the Phase II MANOEUVRE study in FSHD. While emugrobart showed a favorable safety profile and target engagement by reducing mature myostatin, it did not translate into the intended functional outcomes. Specifically, muscle growth and exploratory functional efficacy were neither consistent nor robust enough across study participants to provide sufficient confidence for Phase III development in SMA and FSHD. Emugrobart was well tolerated across both studies, with no serious adverse events or treatment withdrawals. The discontinuation of these studies was not due to safety concerns. As the scientific rationale for continuing to investigate emugrobart in obesity remains strong, this decision does not impact the development of emugrobart in obesity. Obesity is a chronic metabolic disease with symptoms and underlying causes being fundamentally different from neuromuscular conditions like SMA and FSHD. In obesity, muscle quality is not primarily affected by a neurodegenerative (nerve-wasting) or myopathic (muscle-wasting) process and there is generally more myostatin for an anti-myostatin antibody to act on. Consequently, the Phase II development of emugrobart in obesity will continue as planned.
お知らせ • Feb 24Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in JapanSarepta Therapeutics, Inc. announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co. Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. ELEVIDYS is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory individuals with Duchenne ages 3-to less than 8-years-old, a deletion of any portion or the entirety of exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. Chugai announced that ELEVIDYS has been launched in Japan following reimbursement listing, enabling access for eligible patients under the conditional and time limited approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) in May 2025. Chugai will be responsible for postmarketing clinical studies and all case postmarketing surveillance in Japan as part of the Roche Group collaboration to further evaluate long-term efficacy and safety. The approval in Japan was based on efficacy and safety data from the ELEVIDYS clinical development program, including results from the global Phase 3 EMBARK study. EMBARK evaluated ELEVIDYS in ambulatory boys with DMD and demonstrated clinically meaningful improvements in key motor function measures. ADVERSE REACTIONS: The most common adverse reactions (incidence 5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, thrombocytopenia, and troponin-I increased. Report negative side effects of prescription drugs to the FDA.
お知らせ • Jan 29+ 3 more updatesChugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2026.
お知らせ • Oct 27+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Jan 29, 2026Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Jan 29, 2026
お知らせ • Oct 25Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion.Chugai Pharmaceutical Co., Ltd. (TSE:4519) agreed to acquire Renalys Pharma for ¥31 billion on October 24, 2025. A cash consideration of ¥15 billion will be paid by Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd. will pay an earnout/contingent payment of ¥16 billion cash. As part of consideration, ¥31 billion is paid towards common equity of Renalys Pharma. The expected completion of the transaction is November 30, 2025.
お知らせ • Feb 01Chugai Pharmaceutical Co., Ltd. Provides Guidance for the Financial Year Ending December 31, 2025Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year ending December 31, 2025. For the year, company expects revenues of JPY 1,190,000 million, Core operating profit of JPY 570,000 million, Core net income of JPY 410,000 million and Core earnings per share of JPY 250.00.
お知らせ • Jan 31Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 27, 2025.
お知らせ • Jan 16CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519).CHEPLAPHARM K.K. agreed to acquire the Japan business concerning the anti-cancer agent Tarceva® Tablets 25, 100, and 150 from Chugai Pharmaceutical Co., Ltd. (TSE:4519) on January 14, 2025. Upon completion, CHEPLAPHARM group will solely market Tarceva after transferring assets related to Tarceva that are owned by Roche Group and Chugai Pharmaceutical Co., Ltd. (TSE:4519), including the marketing authorization and intellectual property rights (patents and trademarks, etc.). The transfer of the marketing authorization is scheduled to take place on April 1, 2025, and the sales transfer is scheduled to take place in June 2025.
お知らせ • Oct 18+ 3 more updatesChugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Jan 30, 2025Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results at 5:00 PM, Tokyo Standard Time on Jan 30, 2025
お知らせ • Feb 01+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024Chugai Pharmaceutical Co., Ltd. provided consolidated non-audited earnings guidance for the financial year 2024. For the year, company expects revenues of JPY 1,070,000 million, Core operating profit of JPY 460,000 million, Core net income of JPY 335,500 million and Core earnings per share of JPY 204.00.
お知らせ • Dec 07+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results at 5:00 PM, Tokyo Standard Time on Oct 25, 2024
お知らせ • Dec 06Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results at 5:00 PM, Tokyo Standard Time on Feb 01, 2024
お知らせ • Oct 26+ 1 more updateChugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the first nine months and financial year ending December 31, 2023. For the first nine months, the company expects core revenues of ¥837,555 million, Core operating profit of ¥340,537 million, Core net income of ¥250,298 million and Core earnings per share of ¥152.11.For the year, company expects core revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
お知らせ • Feb 03Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023Chugai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the financial year 2023. For the year, company expects revenues of ¥1,070,000 million, Core operating profit of ¥415,000 million, Core net income of ¥306,000 million and Core earnings per share of ¥186.00.
お知らせ • Feb 02+ 1 more updateChugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023Chugai Pharmaceutical Co., Ltd. at its board meeting held on February 2, 2023 approved to distribute retained earnings with the record date being December 31, 2022 for the fiscal year ended December 31, 2022. Dividends per share is JPY 40.00. Total dividends are JPY 65,801 million. Effective date is March 31, 2023.
お知らせ • Nov 01Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results at 5:00 PM, Tokyo Standard Time on Feb 02, 2023
お知らせ • Oct 28+ 2 more updatesChugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023Chugai Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Apr 27, 2023